Immunological dysregulation in the sights of several biologics and “small molecules”

The approval of anti-TNF and anti-IL-17 antibody therapies for moderate to severe courses of hidradenitis suppurativa has significantly improved the drug treatment options for this debilitating and potentially mutilating disease of the terminal hair gland apparatus in recent years. In addition, there is a promising arsenal of immunomodulatory drugs in the pipeline, including interleukin antibodies and JAK-i, as well as nanobodies, BTK and SYK inhibitors.